Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;80(3):491-499.
doi: 10.1007/s12020-023-03352-4. Epub 2023 Mar 31.

How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients

Adnan Zaina  1   2 , Nunzia Prencipe  3 , Elena Golden  4 , Alessandro Maria Berton  3 , Eldad Arad  4 , Ali Abid  4 , Jeryes Shehadeh  5 , Sameer Kassem  6   7 , Ezio Ghigo  3
Affiliations
Review

How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients

Adnan Zaina et al. Endocrine. 2023 Jun.
No abstract available

PubMed Disclaimer

References

    1. A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller et al. Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21, 667–678 (2020) - PubMed - PMC - DOI
    1. G. Vila, J.O.L. Jørgensen, A. Luger, G.K. Stalla, Insulin resistance in patients with acromegaly. Front Endocrinol. (Lausanne) 10, 509 (2019) - PubMed - DOI
    1. D. Cuevas-Ramos, M. Fleseriu, Pasireotide: a novel treatment for patients with acromegaly. Drug Des. Dev. Ther. 10, 227–239 (2016)
    1. M.R. Gadelha, L. Kasuki, D.S.T. Lim, M. Fleseriu, Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40, 268–332 (2019) - PubMed - DOI
    1. I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004). p. - PubMed - DOI

LinkOut - more resources